Modified Response Evaluation Criteria in Solid Tumors (mRECIST)
ورودیهای بالینی بیمار
حداقل ۰.۱ — حداکثر ۵۰ • واحد: cm
حداقل ۰ — حداکثر ۵۰ • واحد: cm
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Complete Response—
- Partial Response—
- Stable Disease—
- Progressive Disease—
The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) calculator is designed for bedside assessing treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments in clinical practice. The resulting score directly guides.
Clinical Guidelines & Evidence
Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.
Clinical Indication
The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) is indicated for bedside clinical practice to support Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: European Association for the Study of the Liver (EASL) guidelines recommend evaluation 1 month after treatment.
mRECIST Response = f(baseline_sum_diameters, current_sum_diameters, enhancement_status). Complete Response: disappearance of arterial enhancement. Partial Response: ≥30% decrease in viable tumor. Progressive Disease: ≥20% increase in viable tumor or new lesions. Stable Disease: neither PR nor PD criteria.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| baseline_sum_diameters | float | Yes | Sum of baseline diameters of viable (enhancing) target lesions in centimeters(cm) |
| current_sum_diameters | float | Yes | Sum of current diameters of viable (enhancing) target lesions in centimeters(cm) |
| intratumoral_enhancement | string | Yes | Presence of intratumoral arterial enhancement in target lesions |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | Complete Response | Disappearance of arterial enhancement |
| — | Partial Response | ≥30% decrease in viable tumor |
| — | Stable Disease | Neither PR nor PD criteria met |
| — | Progressive Disease | ≥20% increase in viable tumor |
Evidence-Based References (EBM)
- Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60. doi: 10.1055/s-0030-1247132.DOI: 10.1055/s-0030-1247132
- Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616-23. doi: 10.1002/cncr.24050.DOI: 10.1002/cncr.24050
- Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118(1):147-56. doi: 10.1002/cncr.26255.DOI: 10.1002/cncr.26255